4//SEC Filing
Diaz Stephanie 4
Accession 0001209191-21-029069
CIK 0001357459other
Filed
Apr 28, 8:00 PM ET
Accepted
Apr 29, 5:47 PM ET
Size
8.7 KB
Accession
0001209191-21-029069
Insider Transaction Report
Form 4
Diaz Stephanie
Director
Transactions
- Award
Stock Option (Right to Buy)
2021-04-27+10,203→ 10,203 totalExercise: $41.20Exp: 2029-06-19→ Common Stock (10,203 underlying) - Award
Stock Option (Right to Buy)
2021-04-27+4,406→ 4,406 totalExercise: $26.85Exp: 2030-07-10→ Common Stock (4,406 underlying)
Footnotes (4)
- [F1]The stock option vested in four equal quarterly installments from June 30, 2019.
- [F2]Received in exchange for a stock option to acquire 375,250 shares of common stock of Leading BioSciences, Inc. ("LBS") for $1.12 per share, pursuant to the Agreement and Plan of Merger, dated December 16, 2020, among Seneca Biopharma Inc., Townsgate Acquisition Sub 1, Inc. and LBS (the "Merger"). Per the terms of the Merger, each share of LBS's common stock was converted into the right to receive 0.02719 shares of Seneca's common stock. In the Merger, the name of the Issuer was changed from Seneca Biopharma, Inc. to Palisade Bio, Inc.
- [F3]The stock option vests according to the following schedule: 25% of the shares underlying the option vests on grant date and the remaining 75% vests in three equal quarterly installments thereafter beginning September 30, 2020.
- [F4]Received in the Merger in exchange for a stock option to acquire 162,069 shares of LBS common stock for $0.73 per share.
Documents
Issuer
PALISADE BIO, INC.
CIK 0001357459
Entity typeother
Related Parties
1- filerCIK 0001850265
Filing Metadata
- Form type
- 4
- Filed
- Apr 28, 8:00 PM ET
- Accepted
- Apr 29, 5:47 PM ET
- Size
- 8.7 KB